AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraStem CellsGraft vs Leukemia EffectBone Marrow TransplantationTreatment OutcomeMyeloablative AgonistsBusulfanTissue DonorsRemission InductionVidarabineRecurrenceGraft vs Tumor EffectGraft SurvivalHistocompatibility TestingLymphocyte TransfusionImmunosuppressive AgentsLeukemia, Myeloid, AcuteMultiple MyelomaLeukemiaRetrospective StudiesCombined Modality TherapySiblingsCord Blood Stem Cell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytomegalovirus InfectionsSalvage TherapyHematopoietic Stem CellsMinor Histocompatibility AntigensDisease-Free SurvivalWhole-Body IrradiationSurvival AnalysisLiver TransplantationLymphocyte DepletionAntilymphocyte SerumMyelodysplastic SyndromesSurvival RateVirus ActivationNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaHistocompatibilityMelphalanChimerismAntineoplastic Combined Chemotherapy ProtocolsHepatic Veno-Occlusive DiseaseCyclophosphamideTime FactorsMesenchymal Stem Cell TransplantationHematopoietic Stem Cell MobilizationCytomegalovirusT-LymphocytesAcute DiseasePrimary MyelofibrosisAnemia, AplasticCell TransplantationKidney TransplantationFollow-Up StudiesHLA AntigensHematologic DiseasesEmbryonic Stem CellsPrognosisLeukemia, Myeloid, Accelerated PhaseAntigens, CD34CytarabineAntibodies, NeoplasmTransplantation ImmunologyImmunosuppressionRoseolovirus InfectionsAntineoplastic AgentsBenzamidesAdult Stem CellsImmunocompromised HostLeukemia, MyeloidLymphoproliferative DisordersFusion Proteins, bcr-ablHodgkin DiseaseReceptors, Purinergic P2X5PyrimidinesNuclear FamilyGraft RejectionLymphoma, Non-HodgkinGranulocyte Colony-Stimulating FactorGanciclovirInfectionPiperazinesCyclosporineFatal OutcomeImmunotherapy, AdoptiveHeart TransplantationOpportunistic InfectionsStomatitisCell DifferentiationLeukocyte Transfusion
Hematopoietic stemChemotherapyAutologous bone marrow traClinicalPreparative regimensPatientsBoneGraftImmunotherapyIsletDonorMalignanciesAntigensMarrowTherapeuticMesenchymalProgenitor cellsStromal cellsReactivationMortalityHSCTAdultPeripheralCancerDestructionRenalRelapseMSCsKidneyCellularResponsesVivoErythropoiesisSevereImmunityTherapiesAcuteDifferentiationChronicClonalTumor cellsIndividual'sToxicityLungMiceRadiationAntigen receptorImmunosuppression
Hematopoietic stem9
Chemotherapy4
  • In recent years, epigenetic therapy has become a treatment option for patients with higher-risk myelodysplastic syndrome (MDS) who are not considered candidates for intensive induction chemotherapy or allogeneic stem cell transplantation (SCT). (biomedcentral.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • The process for administering CAR T-cell therapy is complex, with multiple steps including CAR T-cell manufacturing, lymphodepleting chemotherapy, cellular therapy infusion, and management of short-term and long-term toxicities. (ajmc.com)
  • Current therapies for NSCLC including chemotherapy regimens and drugs that target molecular changes in cancer cells have considerable downsides. (biomedfrontiers.org)
Autologous bone marrow tra1
Clinical15
  • B cell receptor (BCR) signaling plays a critical role in driving proliferation and survival of the malignant clone in chronic lymphocytic leukemia (CLL), supported by the clinical activity of inhibitors targeted toward BCR-associated kinases [ 1 ]. (nature.com)
  • Our findings suggest that cross-circulation can serve as a complementary approach to clinical EVLP to recover injured donor lungs that could not otherwise be utilized for transplantation, as well as a translational research platform for immunomodulation and advanced organ bioengineering. (nature.com)
  • Normothermic ex vivo lung perfusion in clinical lung transplantation. (nature.com)
  • Areas related to clinical and experimental transplantation are also of interest. (lidsen.com)
  • However, recent clinical trials show that micro-encapsulated islets are not fully retrievable after transplantation. (lidsen.com)
  • In this review, we discuss the rationale for MSC-based cell therapy in COPD, the main findings from in vitro and in vivo preclinical COPD model studies, clinical trials in patients with COPD and directions for further research. (bmj.com)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • RQR8 is a 136-amino-acid epitope-based marker/suicide gene that enables clinical selection, cell tracking, and deletion in case of toxicity. (ashpublications.org)
  • A compact marker/suicide gene that utilizes established clinical-grade reagents and pharmaceuticals would be of considerable practical utility to T-cell cancer gene therapy. (ashpublications.org)
  • Multivariable logistic regression assay indicated that lower fasting C-peptide and higher dose of UC-MSC correlated with achievement of clinical remission after transplantation. (biomedcentral.com)
  • While current therapeutic regimens are still focused on controlling clinical symptoms, applications such as immunoregulatory strategies can delay the symptoms and the process of neurodegeneration. (biomedcentral.com)
  • Managed care professionals should have an understanding of the clinical trial data and place in therapy in lymphoma, myeloma, and acute lymphoblastic leukemia as well as guideline recommendations for adverse effect management associated with CAR T-cell therapies. (ajmc.com)
  • In this article, we will provide an overview of clinical islet transplantation (IT) and its advances in the last few years. (touchendocrinology.com)
  • Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia. (lookformedical.com)
  • We then outline preclinical approaches that employ CAR-NK cells for GB immunotherapy, and give an overview on the ongoing clinical development of ErbB2 (HER2)-specific CAR-NK cells currently applied in a phase I clinical trial in glioblastoma patients. (frontiersin.org)
Preparative regimens1
  • This prospective, randomized, phase 2 trial compared safety and efficacy of busulfan with treosulfan based preparative regimens. (bvsalud.org)
Patients18
  • Antiretroviral therapy, the most common treatment for patients with HIV, has been shown to restore CD4+ T cell counts. (wikipedia.org)
  • A total of 808 adult patients underwent transplantation major genotypes of HEV have been recognized. (cdc.gov)
  • All adult patients for whom demics in developing countries, and genotypes 3 and 4 are a blood sample obtained on the day of transplantation was zoonotic and infect humans and several other animals in available were included in the study (n = 700, 529 kidney developing and industrialized countries ( 3 ). (cdc.gov)
  • Patients are conditioned with a variety of preparatory regimens. (hindawi.com)
  • Although kidney transplantation has been an important means for the treatment of patients with end stage of renal disease, the long-term survival rate of the renal allograft remains a challenge. (biomedcentral.com)
  • Despite the high incidence of reactivation of the JC virus in recipients of renal transplantation, a small fraction of patients eventually show JC virus-associated nephropathy, which may lead to rejection of the transplant [ 11 ]. (biomedcentral.com)
  • Indeed, our experiments showed significantly decreased degranulation capacity of primary NK cells from CLL patients expressing low levels of SLAMF1 and SLAMF7. (nature.com)
  • Allogeneic hematopoietic transplantation may be curative in some patients with thalassemia major. (medscape.com)
  • Complete normalization of hemoglobin (complete and major hematological response), is seen in no more than one third of patients, while the remaining continue to experience some degree of anemia (good and partial hematological responses), in some cases requiring regular red blood cell transfusions (minor hematological response). (frontiersin.org)
  • Patients awaiting lung transplantation face high wait-list mortality, as injury precludes the use of most donor lungs. (nature.com)
  • Some patients also showed complete remission according to FISH on bone marrow mononuclear cells and CD34 + peripheral blood cells, as well as by follow-up of somatic mitochondrial DNA mutations. (biomedcentral.com)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • The GOLD 2023 report recommends that triple therapy be considered as an initial treatment only for patients with blood eosinophils ≥300 cells/μL and who have had ≥2 moderate or ≥1 severe exacerbation. (com.ng)
  • Recent evidence indicates that patients already receiving therapy and with blood eosinophils of between 100 and 300 cells/μL, particularly those who have experienced a hospitalization, may also benefit from the addition of an ICS to their existing treatment regimens.35 Further research is needed to explore the use of lower thresholds for triple therapy initiation, thus extending the benefits of this treatment to a broader population. (com.ng)
  • Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
  • Islet transplantation (IT) has emerged as an acceptable method for the treatment of patients with T1DM who suffer for frequent severe hypoglycemia and/or glycemic lability. (touchendocrinology.com)
  • The clonal process may develop at different progenitor cell levels in individual patients, and the clonal progenitor cell may or may not involve T and B lymphocytes [ 10 ]. (medilib.ir)
  • Patients undergoing bone-marrow or stem-cell transplantation are confronted with a range of severe adverse events, including conditioning (e.g. destruction of endogenous immune cells), immunosuppressive medication and life threatening immune reactions (e.g. (biomedcentral.com)
Bone8
  • Bone marrow cells display aberrant morphology and maturation (dysmyelopoiesis), resulting in ineffective blood cell production. (medscape.com)
  • Bone marrow transplantation has a limited role. (medscape.com)
  • MDS develops when a clonal mutation predominates in the bone marrow, suppressing healthy stem cells. (medscape.com)
  • 2 MSCs were first described in the bone marrow where they constitute a small fraction of cells (0.001%-0.01%) that closely interact with haematopoietic cells to support haematopoiesis and skeletal homeostasis. (bmj.com)
  • Mesenchymal stromal cells (MSCs) are non-hematopoietic, multipotent cells that can be sourced from various tissues, including bone marrow, umbilical cord (UC), and adipose tissue. (biomedcentral.com)
  • Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites. (lookformedical.com)
  • Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. (lookformedical.com)
  • The paradox of proliferative bone marrow together with peripheral blood cytopenias in MDS may be explained by increased intramedullary myeloid precursor cell apoptosis [ 6 ]. (medilib.ir)
Graft7
  • Ex vivo techniques enable a more accurate count of the T cells in a graft and also has the option to 'addback' a set number of T cells if necessary. (wikipedia.org)
  • Another method is addition of cells back into the graft, after a comprehensive TCD method, examples are re-introduction of natural killer cells (NK), γδ T-cells and T regulatory cells (Tregs). (wikipedia.org)
  • Early on it was apparent that TCD was good for preventing GVHD, but also led to increased graft rejection, this problem can be solved by transplanting more hematopoietic stem cells. (wikipedia.org)
  • These veto cells can also exert graft vs tumor effect. (wikipedia.org)
  • Transplantation-related issues such as graft versus host disease, graft failure, chronic immunosuppressive therapy, and transplantation-related mortality should be carefully considered prior to proceeding with this approach. (medscape.com)
  • It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (lookformedical.com)
  • or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (lookformedical.com)
Immunotherapy3
  • Collectively, our results identify how and when to administer TLR agonists to augment T cell-based immunotherapy in the absence or presence of host preconditioning for treatment of advanced malignancies. (biomedcentral.com)
  • Nevertheless, ex vivo activation with cytokines can restore cytolytic activity of NK cells against GB, indicating that NK cells have potential for adoptive immunotherapy of GB if potent cytotoxicity can be maintained in vivo . (frontiersin.org)
  • Furthermore, similar to T cells, specific recognition and elimination of cancer cells by NK cells can be markedly enhanced through expression of chimeric antigen receptors (CARs), which provides an opportunity to generate NK-cell therapeutics of defined specificity for cancer immunotherapy. (frontiersin.org)
Islet4
  • Although further improvements may be necessary, this immunosuppression-free approach may replace intraportal islet transplantation in the near future. (lidsen.com)
  • One repeated intravenous dose of allogeneic UC-MSCs is safe in people with recent-onset T1D and may result in better islet β cell preservation during the first year after diagnosis compared to standard treatment alone. (biomedcentral.com)
  • 2 Type 1 diabetes (T1DM), which is caused mainly by an autoimmunemediated destruction of beta cells within the islet of Langerhans, accounts for 5-10 % of the total cases of diabetes worldwide. (touchendocrinology.com)
  • To overcome the need for major surgery and its associated risks, transplantation of islet cells isolated from human cadaveric pancreata has been developed as an alternative therapeutic approach. (touchendocrinology.com)
Donor3
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • [ 14 ] The first successful allogeneic stem cell transplant from an HLA-identical sibling donor was reported in 1982. (medscape.com)
  • An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response. (lookformedical.com)
Malignancies4
  • Research in CAR T-cell therapy is expected to improve tolerability and expand indications to more types of malignancies and earlier phases of disease. (ajmc.com)
  • 2,3 Cellular therapy centers, manufacturers, payers, and policy makers will need to work together to address barriers to care as new CAR T-cell products with improved efficacy and tolerability are approved for use in more diverse malignancies. (ajmc.com)
  • CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES - The hematopoietic pluripotent stem cell is capable of both self-renewal and stepwise differentiation into either the lymphoid or myeloid lineage (which appears to be determined stochastically) [ 1 ]. (medilib.ir)
  • Hematologic malignancies comprise a heterogeneous spectrum of neoplasms including leukemia, lymphoma, and plasma cell neoplasms. (biomedcentral.com)
Antigens8
  • Besides the secretion of pro-inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), the increased expression of receptor repertoire (pattern recognition receptors, PRR) on APCs, mostly macrophages and dendritic cells, occurs as a result of the release of endogenous and exogenous antigens (damage-associated molecular patterns, DAMPs, and pathogen-associated molecular patterns, PAMPs). (hindawi.com)
  • We have created a highly compact marker/suicide gene for T cells combining target epitopes from both CD34 and CD20 antigens (RQR8). (ashpublications.org)
  • Genetic engineering of T cells greatly increases the scope and potency of T-cell therapy: T-cell receptor (TCR) transfer allows targeting of intracellular cancer antigens, whereas chimeric antigen receptors (CARs) allow targeting of surface cancer or lineage-specific antigens. (ashpublications.org)
  • An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. (lookformedical.com)
  • Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains. (lookformedical.com)
  • B-1 cells are found in peritoneal and pleural cavities where they provide first-line defence through antibodies able to bind polysaccharide antigens and repeated motifs that are typically found in microbial cell walls and macromolecules [ 2 , 3 ]. (biomedcentral.com)
  • NK cells contribute to cancer immune surveillance not only by their direct natural cytotoxicity which is triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also by modulating T-cell mediated antitumor immune responses through maintaining the quality of dendritic cells and enhancing the presentation of tumor antigens. (frontiersin.org)
  • Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with ex vivo activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells. (frontiersin.org)
Marrow3
  • As the disease progresses and converts into leukemia, further gene mutation occurs, and a proliferation of leukemic cells overwhelms the healthy marrow. (medscape.com)
  • All are characterized by a hypercellular or hypocellular marrow with impaired morphology and maturation (dysmyelopoiesis) and peripheral blood cytopenias, resulting from ineffective blood cell production. (medscape.com)
  • Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. (lookformedical.com)
Therapeutic5
  • However, in some cases, selective CD4+ T cell tolerance provides a unique therapeutic opportunity to maximize self antigen-targeted immune and antitumor responses without inducing autoimmunity by incorporating self antigen-independent CD4+ T cell epitopes into cancer vaccines. (wikipedia.org)
  • An in silico cell-to-cell interaction analysis highlights the CXCL9/CXCL10-CXCR3 axis and the CD70-CD27 axis as potential therapeutic targets. (pklab.org)
  • Because stromal cells can modulate the functionality of myeloid cells in vitro, targeting stromal-myeloid interactions has become an attractive potential therapeutic strategy. (pklab.org)
  • The preservation or restoration of β cell function in type 1 diabetes (T1D) remains as an attractive and challengeable therapeutic target. (biomedcentral.com)
  • It was previously believed that the main pathogenic mechanism of PD was the loss of dopaminergic neurons and most researchers considered that the therapeutic effect of MSCs on PD was attributable to their cell replacement ability [ 21 , 22 ]. (biomedcentral.com)
Mesenchymal5
  • Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease? (bmj.com)
  • In vitro cell culture and animal studies have demonstrated that mesenchymal stromal cells (MSCs) have the capacity to modify immune responses and to enhance tissue repair. (bmj.com)
  • Mesenchymal stromal cells (MSCs) are cells of non-haematopoietic origin, with the capacity to differentiate into multiple lineages of the mesenchyme, that is, chondrocytes, osteoblasts and adipocytes. (bmj.com)
  • Mesenchymal stromal cells (MSCs) are multipotent cells with high capacity of immunoregulation, which emerged as a promising cell-based therapy for many immune disorders. (biomedcentral.com)
  • In this review, we summarized the progression of the neuroimmune response in PD based on recent studies and focused on the use of mesenchymal stem cell (MSC) therapy and challenges as a strategy of disease-modifying therapy with multiple targets. (biomedcentral.com)
Progenitor cells2
  • Thrombopoietin (TPO) is the principal endogenous regulator of platelet production and also stimulates hematopoietic stem and progenitor cells. (drugpatentwatch.com)
  • 1 Unique MSC-specific markers have not yet been identified, and MSCs constitute a heterogeneous cell population, including both multipotent (stem) cells and progenitor cells and might even contain pluripotent cell fractions. (bmj.com)
Stromal cells2
  • Analysis of supporting stromal cells within the tumor environment demonstrates vascular remodeling within the endothelial cells. (pklab.org)
  • We aimed to investigate how human liver stromal cells impact myeloid cell properties and to understand the utility of a stromal-myeloid coculture system to study these interactions in the context of cirrhosis. (pklab.org)
Reactivation2
  • INTRODUCTION: Herpes zoster (HZ) is caused by endogenous reactivation of latent varicella-zoster virus (VZV) that persists in sensory ganglia after primary infection. (bvsalud.org)
  • As with BKV nephropathy, serologic studies support reactivation of endogenous JCV rather than a primary infection [ 12 , 13 ]. (biomedcentral.com)
Mortality3
  • Primary endpoint was freedom from transplantation (treatment)-related mortality (freedom from TRM), defined as death between Days -7 and +100. (bvsalud.org)
  • Secondary outcomes (transplantation-related mortality [12.0% versus 3.9%]) and overall survival (88.0% versus 96.1%) favored treosulfan. (bvsalud.org)
  • Background & aims: Myeloid cells are key regulators of cirrhosis, a major cause of mortality worldwide. (pklab.org)
HSCT2
  • In contrast, in-vivo TCD is performed using anti-T cell antibodies or, most recently, post-HSCT cyclophosphamide. (wikipedia.org)
  • Experiments show that transplantation of other types of veto cells along with megadose haploidentical HSCT allows to reduce the toxicity of the conditioning regimen, which makes this treatment much safer and more applicable to many diseases. (wikipedia.org)
Adult1
  • In contrast to adult cancers and previous NB studies, we show an increase in inflammatory monocyte cell state when contrasting normal and tumor tissue, while no differences in cytotoxicity and exhaustion score for T cells, nor in Treg activity, are observed. (pklab.org)
Peripheral4
  • At least 6.5 x 10(8) [corrected] mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cyropreserved, and returned intravenously following CBV administration. (shengsci.com)
  • Recent studies have shown that soluble factors elaborated by human T lymphocytes enhance erythroid burst formation by human peripheral blood null cells. (shengsci.com)
  • A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. (lookformedical.com)
  • Myeloproliferative neoplasms (MPN), unlike MDS, usually exhibit terminal myeloid cell expansion in the peripheral blood [ 7 ]. (medilib.ir)
Cancer8
  • One example is antigen-specific CD4+ T cell tolerance, which serves as the primary mechanism restricting immunotherapeutic responses to the endogenous self antigen guanylyl cyclase c (GUCY2C) in colorectal cancer. (wikipedia.org)
  • T cell therapy represents an emerging and promising modality for the treatment of both infectious disease and cancer. (biomedcentral.com)
  • Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer in adults. (pklab.org)
  • Microbial components, such as LPS, are key mediators of total body irradiation (TBI) enhancement, but our ability to strategically use these toll-like receptor (TLR) agonists to bolster the potency of T cell-based therapies for cancer remains elusive. (biomedcentral.com)
  • In cultured primary fibroblasts and cancer cells, the chemotherapeutic drug doxorubicin causes mtDNA damage and release, which leads to cGAS STING dependent ISG activation. (regenerativemedicine.net)
  • The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. (uchicago.edu)
  • The two largest subtypes of lung cancer are adenocarcinoma and squamous cell carcinoma, which together account for about 80% of non-small cell carcinomas (NSCLS). (biomedfrontiers.org)
  • To further confirm that RHAMM is upregulated in NSCLC, we looked at mRNA levels in 57 paired lung adenocarcinomas and 49 pair lung squamous cell carcinomas from The Cancer Genome Atlas (TCGA). (biomedfrontiers.org)
Destruction6
  • Here we report that while exogenous administration of LPS was able to enhance adoptively transferred CD8 + T cells' tumor destruction, LPS treatment alone did not replace individual components of the tripartite ACT regimen, or obviate TBI. (biomedcentral.com)
  • A non-myeloablative lymphodepleting preparative regimen with 5Gy TBI prior to an ACT regimen can induce destruction of B16F10 melanoma in mice by removing cytokine sinks, depleting suppressive T reg cells, transiently ablating myeloid derived suppressor cells (MDSCs) and activating the innate immune system [ 11 ]. (biomedcentral.com)
  • Marker genes enable detection and selection of T cells, whereas suicide genes enable selective destruction of T cells in case of toxicity. (ashpublications.org)
  • Although intensive insulin therapy allows for improved glucose homeostasis, it cannot replace the highly specialized work done by pancreatic islets, neither can it suppress the autoimmune destruction of residual β cells. (biomedcentral.com)
  • Type 1 diabetes (T1DM), which is caused mainly by autoimmune destruction of beta cells, accounts for approximately 5-10 % of all diabetes. (touchendocrinology.com)
  • Autoimmune hemolytic anemia Hemolytic Anemia Hemolytic anemia (HA) is the term given to a large group of anemias that are caused by the premature destruction/hemolysis of circulating red blood cells (RBCs). (lecturio.com)
Renal1
Relapse1
MSCs3
  • Following early observations that MSCs inhibit T-cell proliferation, 9 MSCs were found to interact with the majority of innate and adaptive immune cells. (bmj.com)
  • The objective of this study was to examine the efficacy and safety of one repeated transplantation of allogeneic MSCs in individuals with T1D. (biomedcentral.com)
  • Twenty-seven subjects (MSC-treated group) received an initial systemic infusion of allogeneic UC-MSCs, followed by a repeat course at 3 months, whereas the control group ( n = 26) only received standard care based on intensive insulin therapy. (biomedcentral.com)
Kidney1
Cellular5
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • The current understanding of aGVHD pathogenesis can be summarized as (1) initial tissue damage induced by the conditioning regimen followed by the denudation of auto- and alloantigens accompanied by massive inflammatory cytokine secretion ("cytokine storm") activating APCs, (2) auto- and alloantigen presentation mediated by APCs together with the costimulatory signaling prime donor's cytotoxic T lymphocytes and their proliferation, and (3) the migration of activated cellular effectors toward GVHD target tissues. (hindawi.com)
  • The concept of enhancing cellular immunity through the transfer of ex-vivo expanded T cells was pioneered by Greenberg et al. (biomedcentral.com)
  • Thus, during normal hematopoiesis, there exists a cellular hierarchy headed by a stable population of pluripotent stem cells that generate lineage-specific progenitors, which differentiate into the various types of mature blood cells [ 2 ]. (medilib.ir)
  • Many of these factors stem from the location of the epitope that can affect accessibility of the antibody to the epitope at a cellular or molecular level, direct inhibition of target antigen activity, conservation of function despite escape mutations, and even non-competitive inhibition sites. (preprints.org)
Responses4
  • T-cell depletion (TCD) is the process of T cell removal or reduction, which alters the immune system and its responses. (wikipedia.org)
  • Overexpression of SLAMF1 or SLAMF7 in IGHV mutated CLL cell models resulted in reduced proliferation and impaired responses to BCR ligation, whereas the knockout of both receptors showed opposing effects and increased sensitivity toward inhibition of components of the BCR pathway. (nature.com)
  • They are known to be involved in the regulation of NK and T cell responses, mostly by homotypic interactions except for SLAMF2 (CD48) and SLAMF4 that interact with each other [ 10 ]. (nature.com)
  • 1 CAR T-cell therapy pivotal trials demonstrated unprecedented overall response rates (ORRs) and complete responses (CRs) that led to the FDA approval of 5 CAR T-cell products: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), brexucabtagene autoleucel (brexu-cel), and idecabtagene vicleucel (ide-cel). (ajmc.com)
Vivo2
  • We have tested the functionality of RQR8 in vitro and in vivo as well as in combination with T-cell engineering components. (ashpublications.org)
  • In addition, mtDNA stress in TFAM-deficient mouse melanoma cells produces tumours that are more resistant to doxorubicin in vivo. (regenerativemedicine.net)
Erythropoiesis1
  • This strategy treats the anemia and suppresses endogenous erythropoiesis so that extramedullary hematopoiesis and skeletal changes are suppressed. (medscape.com)
Severe1
Immunity2
  • Since SLAMF receptors play a role in NK cell biology, we reasoned that these receptors may impact NK cell-mediated CLL immunity. (nature.com)
  • To determine the mechanisms of how innate immune activation via lymphodepletion potentiated antitumor T cell immunity, we utilized the pmel-1 melanoma mouse model. (biomedcentral.com)
Therapies2
  • While effective, broad use of CAR T-cell therapies is limited by potential for life-threatening toxicities, challenges related to manufacturing a patient-specific product, high costs and inadequate reimbursement, and incomplete or unsustained disease response. (ajmc.com)
  • CAR T-cell therapies are limited by the potential to cause life-threatening toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). (ajmc.com)
Acute1
Differentiation2
  • MDS affects hematopoiesis at the stem cell level, as indicated by cytogenetic abnormalities, molecular mutations, and morphologic and physiologic abnormalities in maturation and differentiation of one or more of the hematopoietic cell lines. (medscape.com)
  • In 2001, two independent groups showed that the antiepileptic drug valproic acid (VPA) also has HDAC inhibitory activity and induces differentiation of malignant myeloid cells, an ability that is enhanced by all-trans retinoic acid (ATRA) (Göttlicher et al. (biomedcentral.com)
Chronic2
  • Chronic Granulomatous Disease , autoimmune diseases Autoimmune diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. (lecturio.com)
  • Clonal studies in the chronic myeloid disorders - Genetic and enzyme studies based upon X-chromosome inactivation patterns have revealed a multipotent progenitor cell origin for the neoplastic clone in both MDS [ 8 ] and MPN [ 9 ]. (medilib.ir)
Clonal1
  • Numbat exploits the evolutionary relationships between subclones to iteratively infer single-cell copy number profiles and tumor clonal phylogeny. (pklab.org)
Tumor cells4
  • Single-cell transcriptomic analysis of tumor cells from the primary tumors reveals a distinct transcriptional signature that is predictive of metastatic potential and patient survival. (pklab.org)
  • Our findings provide biological insights into the interplay between tumor cells and the ccRCC microenvironment. (pklab.org)
  • A cell line derived from cultured tumor cells. (lookformedical.com)
  • Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. (uchicago.edu)
Individual's2
  • However, over time, an individual's immune system can no longer continue to replace CD4+ T cells. (wikipedia.org)
  • Transplantation of an individual's own tissue from one site to another site. (lookformedical.com)
Toxicity1
  • Marker genes enable measurement of transduction and allow selection of transduced cells, whereas suicide genes allow selective deletion of administered T cells in the face of toxicity. (ashpublications.org)
Lung5
  • Here we demonstrate that acutely injured human lungs declined for transplantation, including a lung that failed to recover on EVLP, can be recovered by cross-circulation of whole blood between explanted human lungs and a Yorkshire swine. (nature.com)
  • Cell replacement in human lung bioengineering. (nature.com)
  • Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. (biomedfrontiers.org)
  • The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers, but its role in primary and metastatic non-small cell lung carcinoma (NSCLC) remains to be determined. (biomedfrontiers.org)
  • Moreover, shRNA-mediated knockdown of RHAMM reduced the migratory ability of two lung adenocarcinoma cell lines, H1975 and H3255. (biomedfrontiers.org)
Mice4
  • B16F10-bearing mice were preconditioned with 5Gy TBI and given a tripartite ACT therapy (consisting of transferred pmel-1 CD8 + T cells, vaccination with fowlpox encoding gp100, and IL-2) along with TLR4 agonist LPS. (biomedcentral.com)
  • Finally, TBI was no longer needed to regress tumors in mice who were depleted of host CD4 + T cells, given a tripartite ACT regimen and then treated with low dose LPS. (biomedcentral.com)
  • Mice lacking Fh1 in pancreatic β cells (Fh1βKO mice) appear normal for 6-8 weeks but then develop progressive glucose intolerance and diabetes. (shengsci.com)
  • According with studies of cell transplants performed in transgenic mice, B-1 population can be divided in two further subset (B-1a and B-1b), which display different phenotypes, origins and functions. (biomedcentral.com)
Radiation1
  • Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. (biomedcentral.com)
Antigen receptor1
  • Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)
Immunosuppression1